Evidence map›Paper›PMID 34268084›Full record

ArticleGland surgery2021

A plasma-derived extracellular vesicle mRNA classifier for the detection of breast cancer.

Geng-Xi Cai, Li Lin, Xiang-Ming Zhai, Zhi-Wei Guo, Ying-Song Wu, Guo-Lin Ye, Qing Liu, Lu-Shi Chen, Guan-Yu Xing, Qiao-Hong Zhao and 3 more

Abstract read
In one paragraph

Article in Gland surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Role of TIM-1 in the development and treatment of tumours.Frontiers in cell and developmental biology · 2024
    Review
  7. Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Geng-Xi CaiBreast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Li LinKey Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, School of Laboratory Medical and Biotechnology, Southern Medical University, Guangzhou, China.
Xiang-Ming ZhaiKey Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, School of Laboratory Medical and Biotechnology, Southern Medical University, Guangzhou, China.
Zhi-Wei GuoKey Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, School of Laboratory Medical and Biotechnology, Southern Medical University, Guangzhou, China.
Ying-Song WuKey Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, School of Laboratory Medical and Biotechnology, Southern Medical University, Guangzhou, China.
Guo-Lin YeDepartment of Breast Surgery, The First People's Hospital of Foshan, Foshan, China.
Qing LiuDepartment of Breast Surgery, The First People's Hospital of Foshan, Foshan, China.
Lu-Shi ChenDepartment of Breast Surgery, The First People's Hospital of Foshan, Foshan, China.
Guan-Yu XingDepartment of Breast Surgery, The First People's Hospital of Foshan, Foshan, China.
Qiao-Hong ZhaoDepartment of Breast Surgery, The First People's Hospital of Foshan, Foshan, China.
Li-Ling TangDepartment of Breast Surgery, The First People's Hospital of Foshan, Foshan, China.
Shun-He MaiDepartment of Breast Surgery, The First People's Hospital of Foshan, Foshan, China.
Bo-Jian YeDepartment of Breast Surgery, The First People's Hospital of Foshan, Foshan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAccording to the global cancer burden data released in 2020, breast cancer (BC) has become the most common cancer in the world. Similar to those of other cancers, the present methods used in clinic for diagnosing early BC are invasive, inaccurate, and insensitive. Hence, new non-invasive methods capable of early diagnosis are needed.

methodsWe applied next-generation sequencing and analyzed the messenger RNA (mRNA) profiles of plasma extracellular vesicles (EVs) derived from 14 BC patients and 6 patients with benign breast lesions. We used 3 regression models, namely support vector machine (SVM), linear discriminate analysis (LDA), and logistic regression (LR), to develop classifiers for use in making predictive BC diagnoses; and used 259 plasma samples, including those obtained from 144 patients with BC, 72 patients with benign breast lesions, and 43 healthy women, which were divided into training groups and validation groups to verify their performances as classifiers by quantitative reverse transcription polymerase chain reaction (RT-qPCR). The area under the curve (AUC) and accuracy, sensitivity, and specificity of the classifiers were cross-validated with the leave-1-out cross-validation (LOOCV) method.

resultsAmong all combinations assessed with the 3 different regression models, an 8-mRNA combination, named EXOB

conclusionsWe developed a high-performing predictive classifiers including 8 mRNAs from plasma extracellular vesicles for diagnosing breast cancer.

Indexed as

Breast cancer (BC)diagnosisextracellular vesicles (EVs)messenger RNAs (mRNAs)predictive classifier

Identifiers

PMID34268084
PMCPMC8258891

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.